These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 34909030)

  • 1. Neuroenhancement: State of the Art and Future Perspectives.
    Marazziti D; Avella MT; Ivaldi T; Palermo S; Massa L; Vecchia AD; Basile L; Mucci F
    Clin Neuropsychiatry; 2021 Jun; 18(3):137-169. PubMed ID: 34909030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students.
    Maier LJ; Liechti ME; Herzig F; Schaub MP
    PLoS One; 2013; 8(11):e77967. PubMed ID: 24236008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Neuroenhancement in the Field of Economics-Poll Results from an Online Survey.
    Dietz P; Soyka M; Franke AG
    Front Psychol; 2016; 7():520. PubMed ID: 27148128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It Was Me on a Good Day": Exploring the Smart Drug Use Phenomenon in England.
    Vargo EJ; Petróczi A
    Front Psychol; 2016; 7():779. PubMed ID: 27303339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroenhancement in French and Romanian University Students, Motivations and Associated Factors.
    Brumboiu I; Porrovecchio A; Peze T; Hurdiel R; Cazacu I; Mogosan C; Ladner J; Tavolacci MP
    Int J Environ Res Public Health; 2021 Apr; 18(8):. PubMed ID: 33917251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The is and ought of the Ethics of Neuroenhancement: Mind the Gap.
    Forlini C; Hall W
    Front Psychol; 2015; 6():1998. PubMed ID: 26779100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.
    Daubner J; Arshaad MI; Henseler C; Hescheler J; Ehninger D; Broich K; Rawashdeh O; Papazoglou A; Weiergräber M
    Neural Plast; 2021; 2021():8823383. PubMed ID: 33519929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people.
    Boot BP; Partridge B; Hall W
    Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological neuroenhancement and brain doping : Chances and risks].
    Franke AG; Lieb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Aug; 53(8):853-9. PubMed ID: 20700786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On pharmacological neuroenhancement as part of the new neurorights' pioneering legislation in Chile: a perspective.
    Cornejo-Plaza MI; Saracini C
    Front Psychol; 2023; 14():1177720. PubMed ID: 37533709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers.
    Jebrini T; Manz K; Koller G; Krause D; Soyka M; Franke AG
    Front Psychiatry; 2021; 12():771126. PubMed ID: 34975573
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence of the use of prescription stimulants as "study drugs" by UK university students: A brief report.
    Jones F; Newton PM
    Brain Behav; 2024 Feb; 14(2):e3419. PubMed ID: 38346719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological neuroenhancement and the ability to recover from stress - a representative cross-sectional survey among the German population.
    Bagusat C; Kunzler A; Schlecht J; Franke AG; Chmitorz A; Lieb K
    Subst Abuse Treat Prev Policy; 2018 Oct; 13(1):37. PubMed ID: 30348181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background.
    Weiergräber M; Ehninger D; Broich K
    Med Monatsschr Pharm; 2017 Apr; 40(4):154-64. PubMed ID: 29952165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Realistic Are the Scientific Assumptions of the Neuroenhancement Debate? Assessing the Pharmacological Optimism and Neuroenhancement Prevalence Hypotheses.
    Schleim S; Quednow BB
    Front Pharmacol; 2018; 9():3. PubMed ID: 29403383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroenhancement in healthy subject? A French case study].
    Micoulaud-Franchi JA; Vion-Dury J; Lancon C
    Therapie; 2012; 67(3):213-21. PubMed ID: 22874487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Options, limits and ethics of pharmacological neuroenhancement].
    Normann C; Boldt J; Maio G; Berger M
    Nervenarzt; 2010 Jan; 81(1):66-74. PubMed ID: 19851745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective.
    Franke AG; Northoff R; Hildt E
    Pharmacopsychiatry; 2015 Nov; 48(7):256-64. PubMed ID: 26252723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of and motives for pharmacological neuroenhancement in Switzerland--results from a national Internet panel.
    Maier LJ; Haug S; Schaub MP
    Addiction; 2016 Feb; 111(2):280-95. PubMed ID: 26189457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life context of pharmacological academic performance enhancement among university students--a qualitative approach.
    Hildt E; Lieb K; Franke AG
    BMC Med Ethics; 2014 Mar; 15():23. PubMed ID: 24606831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.